Intestinal bacteria produce hormone -like proteins that regulate blood sugar weight and level

Our intestines are home for trillion microorganisms that produce substances capable of regulating all organ organs using a bloodstream and intestinal nervous system. However, only little is known about the impact of most bacteria that make up our microbiome. Now an international team of scientists under the leadership of the University of Copenhagen has identified a common specific bacterial strain that can open the door to a completely new class of therapeutics.

This bacterium produces two proteins that partly resemble a hormonal irpion. Izin is released by muscles during physical activity and plays a role in fat metabolism.

The newly discovered signaling proteins called Rordep1 and Rordep2 affect the hormonal balance of the body and affect the weight, bone density and blood sugar levels.

“We have found that the number of bacteria producing the RODEP may differ by up to 100,000 times between individuals and people with a high level of these bacteria are slimmer,” says Yong Fan, an assistant to the contractor at Novo Nordisk Foundation Center for Copenhagen and the main author of the study, which has just been published in a prestigious daily.

Regulates body weight and blood sugar levels

In the study, researchers describe how the RODEP Białeny increases their own hormone production, such as GLP-1 and Pyy, which help regulate the appetite and blood sugar, as well as insulin, which is necessary to maintain a stable blood sugar level. At the same time, they suppress another hormone, GIP, which can contribute to weight gain. RODEP proteins also directly increase fat burning.

In experiments with rats and mice, which have received either intestinal bacteria producing Rordep or RODEP proteins themselves, we observed reduced weight gain and lower blood sugar levels, along with increased bone density. It is exciting that for the first time we mapped intestinal bacteria that change our hormonal balance. “

Yong Fan, assistant professor Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen

Changing the paradigm in the treatment of chronic diseases

Research on the role of intestinal bacteria in human health led researchers from the University of Copenhagen to establish a biotechnology company Gutecrine two years ago, with the financial support of the University.

The first clinical trials are currently underway. In one study, healthy participants receive live bacteria that produce a RODEP to examine how they affect human biology. Testing the RODEP1 protein activities is another study.

We are now translating our basic research on people to examine whether the RODEP producing bacteria or RODEP proteins – in their natural or chemically modified form – can be used as the basis of a new class of biological drugs known as pharmabiotics. “

Professor Oluf Pedersen from the University of Copenhagen, project leader and senior author of The New Study

He adds: “Looking from 10 to 15 years, our goal is to test the potential of bacteria producing Rordep for both prevention and treatment. We want to examine whether they can function as a second generation probiotic for second-generation diseases, in order to prevent joint chronic disease-and or white RODEP in the forms, they can be developed in the form of the future of medication in a cardiovascular drug.

The research was conducted in cooperation with scientists from the University of Copenhagen, Herlev-Gentofte Hospital, Zealand, University Hospital, Novo Nordisk A/S, Technical University of Denmark, Steno Diabetes Center and Chongqing Medical University.